Trending...
- California: Governor Newsom announces appointments 12.4.24
- IEI Technology USA Launches IMBAX-SP6: High-Performance ATX Motherboard for Edge AI Applications
- Ushio America to Exclusively Distribute Kooptech-Bio® LEGO® Washing Unit in North America
MONTREAL, Nov. 20, 2024 ~ Thryv Therapeutics Inc., a clinical-stage biotechnology company, has recently announced the appointment of Dr. Amy Sehnert as their new Chief Medical Officer (CMO). With her extensive experience in pediatric cardiology and her background in innovative biotech companies, Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics' expanding cardiometabolic product portfolio.
Dr. Sehnert brings over 20 years of experience as a serial and founding medical lead at various biotech companies, where she has introduced precision diagnostics and therapeutics to the clinic. Most recently, she served as Vice President and Global Program Lead for cardiovascular assets at Bristol Myers Squibb (BMS). During her time at BMS, she played a crucial role in the development and approval of Camzyos®, a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). Her contributions to this development ultimately led to BMS's acquisition of MyoKardia, Inc. for $14 billion in 2020.
Expressing her excitement about joining Thryv Therapeutics, Dr. Sehnert said, "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey. Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide."
More on The Californer
Aside from her work in cardiovascular diseases, Dr. Sehnert has also made significant contributions in other fields of medicine such as maternal-fetal health, oncology, and genomics. She was one of the early pioneers in non-invasive prenatal testing (NIPT) and cell-free DNA applications that are now widely used in clinical settings.
Dr. Sehnert holds a Doctor of Medicine degree from the University of Minnesota and completed her residency in Pediatrics at the University of Colorado. She also completed a fellowship in Pediatric Cardiology at UCSF and has held faculty appointments at both UCSF and Stanford University. In 2022, she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and is considered an internationally recognized expert in her field.
Thryv Therapeutics' CEO, Paul F. Truex, expressed his excitement about Dr. Sehnert joining the team, saying, "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases, along with her leadership qualities, will be invaluable as we enter the next phase of clinical development for our SGK1 portfolio."
More on The Californer
Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. Truex also expressed his gratitude for Dr. Sager's contributions to Thryv Therapeutics' portfolio thus far and his commitment to finding treatments for patient communities.
In conclusion, Thryv Therapeutics is excited to have Dr. Amy Sehnert join their team as their new Chief Medical Officer. With her expertise and experience in precision medicine and clinical development, she will play a crucial role in advancing Thryv Therapeutics' cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1).
Dr. Sehnert brings over 20 years of experience as a serial and founding medical lead at various biotech companies, where she has introduced precision diagnostics and therapeutics to the clinic. Most recently, she served as Vice President and Global Program Lead for cardiovascular assets at Bristol Myers Squibb (BMS). During her time at BMS, she played a crucial role in the development and approval of Camzyos®, a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). Her contributions to this development ultimately led to BMS's acquisition of MyoKardia, Inc. for $14 billion in 2020.
Expressing her excitement about joining Thryv Therapeutics, Dr. Sehnert said, "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey. Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide."
More on The Californer
- Long Beach Health Department Hosts Third Annual Kwanzaa Experience Event
- Breaking: Federal Court Says City Of Los Angeles Must Answer Homelessness Lawsuit
- VetsinTech Marks Veterans Day Milestone: 2,000+ Veterans Trained in Cybersecurity Through Craig Newmark Philanthropies Partnership
- Provarity Secures $7 Million in Seed Funding to Transform Presales Enablement
- California invests over $100 million to build safe walking and biking routes in disadvantaged communities
Aside from her work in cardiovascular diseases, Dr. Sehnert has also made significant contributions in other fields of medicine such as maternal-fetal health, oncology, and genomics. She was one of the early pioneers in non-invasive prenatal testing (NIPT) and cell-free DNA applications that are now widely used in clinical settings.
Dr. Sehnert holds a Doctor of Medicine degree from the University of Minnesota and completed her residency in Pediatrics at the University of Colorado. She also completed a fellowship in Pediatric Cardiology at UCSF and has held faculty appointments at both UCSF and Stanford University. In 2022, she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and is considered an internationally recognized expert in her field.
Thryv Therapeutics' CEO, Paul F. Truex, expressed his excitement about Dr. Sehnert joining the team, saying, "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases, along with her leadership qualities, will be invaluable as we enter the next phase of clinical development for our SGK1 portfolio."
More on The Californer
- Comp U Floor ERP vs. FloorZap: Discover the Best Flooring Business Software
- Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers
- IP4Pros Launches Exclusive AI-Powered Patent Drafting Tool for Graduating Law Students
- NPower Receives $1M Grant from Northrop Grumman Foundation to Expand Tech Training for Transitioning Military Service Members
- 418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. Truex also expressed his gratitude for Dr. Sager's contributions to Thryv Therapeutics' portfolio thus far and his commitment to finding treatments for patient communities.
In conclusion, Thryv Therapeutics is excited to have Dr. Amy Sehnert join their team as their new Chief Medical Officer. With her expertise and experience in precision medicine and clinical development, she will play a crucial role in advancing Thryv Therapeutics' cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1).
Filed Under: Business
0 Comments
Latest on The Californer
- City of Long Beach Encourages Community to Be Storm Smart
- Piano to Zanskar Conducts a Musical Journey Across the Himalayas on Documentary Showcase
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- South Coast AQMD Awards $109 Million to Advance Zero-Emission Infrastructure in Underserved Communities
- ATTN: BUSINESS: 'Tis the Season, and here is a GREAT BUSINESS GIFT For Every Business in the World
- The Role Of Temperature Calibration In Protecting Food Safety
- Cracking the Code of Modern Work: How Lubyc Is Making Life Easier, Business Better (and More Fun)
- The Score Album for "The Lost Weekend: A Love Story" Released Today
- City of Long Beach Offering Annual Holiday Treecycling Program for Residents
- Youth Group Makes History as First Visitors to National Electronics Museum
- New Preclinical Data Demonstrate Potential of Capsida's IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
- Long Beach Parks, Recreation and Marine to Offer Free Winter Fun Days Recreation Program for Youth Starting December 23
- Shape the Future of OpenSSL: Election Period Open Now!
- LIB Empowers Uzbekistan's Automotive Industry: A New Era of Quality Assurance
- TijaraIQ.com Launches as Iraq's Free Marketplace for Buying, Selling, and Creating Opportunities
- 'Man Of The Hour' and 'Sommet Dame' To Be Consolidated Into A New Platform
- Big News!! Best Sac Homes Group Partners with LPT Realty
- Long Beach Airport Wraps Up Centennial Celebration with Time Capsule, New Slogan and Pop-Up Pickleball Courts
- California: Governor Newsom announces appointments 12.5.24